The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Hearing technology company Nuheara (NUH) has been awarded phase two works, worth $2 million, from U.S.-based, multinational IT company HP
  • It follows the completion of proof of concept for an earbud variant, details of which are confidential
  • The extension includes a purchase order for works associated with the development and engineering of the buds
  • Nuheara partnered with HP in August and commenced work on accompanying software services
  • Shares opened 1.9 per cent lower at 5.2 cents

Hearing technology company Nuheara (NUH) has been awarded phase two works under a collaboration agreement with HP, worth $2 million.

It follows the completion of a proof of concept for an earbud variant under development for the U.S.-based, multinational IT company, details of which are confidential.

The phase two extension includes a purchase order for works associated with the development and engineering of the buds.

CEO Justin Miller said the multi-staged partnership is a strong vote of confidence in the company’s technological innovation.

“This next stage of the HP collaboration agreement is the result of Nuheara’s globally recognised leadership in hearables innovation,” Justin stated.

“We are looking forward to deepening this strategic OEM [original equipment manufacturer] partnership over the coming months,” he added.

Nuheara partnered with HP in August and commenced work on accompanying software services.

Shares have been trading 1.9 per cent lower at 5.2 cents at 10:45 am AEDT.

NUH by the numbers
More From The Market Online

Inoviq closes the gap on blood test results for ovarian cancer

INOVIQ has announced encouraging blood test identification results for ovarian cancer.

Paradigm Biopharma on track to US Phase III osteo program

Paradigm Biopharma has announced its completion of a submission to the US FDA to progress to…

Firebrick Pharma’s US launch of Nasal Spray is nothing to be sneezed at

Australian pharmaceutical developer, Firebrick Pharma (ASX:FRE) has launched its latest product, Nasodine Nasal Spray, in the…

AVITA Medical drops revenue forecast for Q1

AVITA Medical (ASX:AVH) provided an update on its anticipated revenue for Q1 2024 - and has…